Voyager Therapeutics VYGR
NASDAQ VYGR
$2.69 +0.05 (+1.89%)
As of: Sep 30, 2026 · 2:44 PM EDT

Voyager Therapeutics (VYGR) Interest Coverage Ratio (2014 - 2016)

Updated

Voyager Therapeutics' (VYGR) Interest Coverage Ratio was -33.99 for Q2 2016, compared with -55.10 a year earlier.

Analysis

Voyager Therapeutics (VYGR) Interest Coverage Ratio (2014 - 2016) Analysis & Trends

Over the twelve months ended Jun 30, 2016, Voyager Therapeutics' Interest Coverage Ratio came in at -34.77; for FY2015, it was -1.06.

  • By year, Interest Coverage Ratio came in at -3.68 in FY2014 and -56.21 in FY2013.
  • Five-year quarterly Interest Coverage Ratio spans a low of -55.10 in Q2 2015 and a high of -0.50 in Q1 2015.
  • Per Business Quant data, the three quarters before Q2 2016 came in at -26.76 (Q1 2016), -47.39 (Q4 2015) and -39.40 (Q3 2015).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 25.41
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn -
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 10.28
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 7.27
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 5.22
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -42.08
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Voyager Therapeutics 161.76 Mn -501.43 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2016 -33.99
Mar 31, 2016 -26.76
Dec 31, 2015 -47.39
Sep 30, 2015 -39.40
Jun 30, 2015 -55.10
Mar 31, 2015 -0.50
Dec 31, 2014 -11.56
Sep 30, 2014 -5.24
API Access

Voyager Therapeutics Interest Coverage Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-coverage-ratio&ticker=VYGR&period=max&api_key=YOUR_API_KEY